Log in to save to my catalogue

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2328773644

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

When used as maintenance therapy, the PARP inhibitor olaparib provided a significant progression-free survival benefit in women with ovarian cancer who had a response to primary chemotherapy, particularly in those whose tumors were deficient in homologous recombination (e.g.,
BRCA
-mutated tumors). Hematologic toxic effects were observed.

Alternative Titles

Full title

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2328773644

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2328773644

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa1911361

How to access this item